Teriparatide transdermal - TransPharma

Drug Profile

Teriparatide transdermal - TransPharma

Alternative Names: hPTH (1-34); ViaDerm-hPTH (1-34); ViaDor-hPTH (1-34)

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator TransPharma Medical
  • Developer Eli Lilly; TransPharma Medical
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2011 Eli Lilly completes a phase II trial in Osteoporosis in Argentina, Estonia, Hungary, Mexico and Romania (NCT01011556)
  • 11 May 2011 Eli Lilly completes a Phase-I clinical trial in Osteoporosis in USA, Germany and the United Kingdom (NCT01250145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top